BIOMAT Database Logo BIOMAT Database Logo

[The role of prophylactic use of pegylated recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF) in breast cancer receiving adjuvant chemotherapy]. 2018

J Y Zhang, and Y X Liu, and H Wang, and L Mi, and G H Song, and H F Jiang, and Y Yan, and B Shao, and W Y Kong, and R Y Zhang, and R Ran, and X R Liu, and J Wang, and Y T Lin, and H P Li
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.

Objectives: To investigate the efficacy and safety of prophylactic use of pegylated recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF) in breast cancer receiving docetaxel as adjuvant chemotherapy. Methods: A total of 58 patients with breast cancer receiving adjuvant chemotherapy with docetaxel were included between January 2014 to October 2017. Prophylactic use of PEG-rhG-CSF was administered.Patients were further divided into two groups according to the frequency of PEG-rhG-CSF use: frequent use group (≥3 cycles) and non-frequent use group (<3 cycles). Results: There were significant differences in the incidence rates of grade 3/4 neutropenia between the prophylactic group and non-prophylactic group in cycle 1-3(P<0.05). Less febrile neutropenia (FN) was also noted in the prophylactic group compared with the non-prophylactic group in cycle 1 and cycle 3 (P<0.05). Grade 3/4 neutropenia and FN were less in the frequent use of group compared with the non-frequent use group(P<0.001). The most common side effects of PEG-rhG-CSF included fatigue (10.2%), bone joint pain(50.8%), and 2 patients (3.4%) refused further treatment because of bone joint pain. Conclusions: PEG-rhG-CSF should be prophylactically used for preventing neutropenia and febrile neutropenia in breast cancer patients receiving adjuvant chemotherapy with docetaxel regimen.

UI MeSH Term Description Entries
D011092 Polyethylene Glycols Polymers of ETHYLENE OXIDE and water, and their ethers. They vary in consistency from liquid to solid depending on the molecular weight indicated by a number following the name. They are used as SURFACTANTS, dispersing agents, solvents, ointment and suppository bases, vehicles, and tablet excipients. Some specific groups are NONOXYNOLS, OCTOXYNOLS, and POLOXAMERS. Macrogols,Polyoxyethylenes,Carbowax,Macrogol,Polyethylene Glycol,Polyethylene Oxide,Polyethyleneoxide,Polyglycol,Glycol, Polyethylene,Glycols, Polyethylene,Oxide, Polyethylene,Oxides, Polyethylene,Polyethylene Oxides,Polyethyleneoxides,Polyglycols,Polyoxyethylene
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D016179 Granulocyte Colony-Stimulating Factor A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines. Colony-Stimulating Factor, Granulocyte,G-CSF,Myeloid Growth Factor,Colony Stimulating Factor, Granulocyte,Factor, Granulocyte Colony-Stimulating,Factor, Myeloid Growth,Granulocyte Colony Stimulating Factor,Growth Factor, Myeloid
D017024 Chemotherapy, Adjuvant Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment. Adjuvant Chemotherapy,Drug Therapy, Adjuvant,Adjuvant Drug Therapy

Related Publications

J Y Zhang, and Y X Liu, and H Wang, and L Mi, and G H Song, and H F Jiang, and Y Yan, and B Shao, and W Y Kong, and R Y Zhang, and R Ran, and X R Liu, and J Wang, and Y T Lin, and H P Li
[Effect of recombinant human granulocyte colony stimulating factor (rhG-CSF) in patients receiving chemotherapy--phase I study].
May 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
J Y Zhang, and Y X Liu, and H Wang, and L Mi, and G H Song, and H F Jiang, and Y Yan, and B Shao, and W Y Kong, and R Y Zhang, and R Ran, and X R Liu, and J Wang, and Y T Lin, and H P Li
Effect of recombinant human granulocyte colony-stimulating factor in patients receiving chemotherapy for urogenital cancer. Urological rhG-CSF Study Group.
April 1992, The Journal of urology,
J Y Zhang, and Y X Liu, and H Wang, and L Mi, and G H Song, and H F Jiang, and Y Yan, and B Shao, and W Y Kong, and R Y Zhang, and R Ran, and X R Liu, and J Wang, and Y T Lin, and H P Li
A clinical study of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in preventing neutropenia during concurrent chemoradiotherapy of cervical cancer.
June 2021, BMC cancer,
J Y Zhang, and Y X Liu, and H Wang, and L Mi, and G H Song, and H F Jiang, and Y Yan, and B Shao, and W Y Kong, and R Y Zhang, and R Ran, and X R Liu, and J Wang, and Y T Lin, and H P Li
Recombinant human granulocyte colony-stimulating factor (rhG-CSF) promotes in vitro platelet aggregation.
October 2007, Hematology (Amsterdam, Netherlands),
J Y Zhang, and Y X Liu, and H Wang, and L Mi, and G H Song, and H F Jiang, and Y Yan, and B Shao, and W Y Kong, and R Y Zhang, and R Ran, and X R Liu, and J Wang, and Y T Lin, and H P Li
Effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on circulating platelets.
July 1992, Annals of hematology,
J Y Zhang, and Y X Liu, and H Wang, and L Mi, and G H Song, and H F Jiang, and Y Yan, and B Shao, and W Y Kong, and R Y Zhang, and R Ran, and X R Liu, and J Wang, and Y T Lin, and H P Li
A prospective, randomized clinical trial of emergency treatment of chemotherapy-induced neutropenia and febrile neutropenia by pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF).
January 2023, British journal of clinical pharmacology,
J Y Zhang, and Y X Liu, and H Wang, and L Mi, and G H Song, and H F Jiang, and Y Yan, and B Shao, and W Y Kong, and R Y Zhang, and R Ran, and X R Liu, and J Wang, and Y T Lin, and H P Li
Schedule-intensified M-VAC chemotherapy for advanced urothelial cancer with recombinant human granulocyte colony stimulating factor (rhG-CSF).
June 1994, International journal of urology : official journal of the Japanese Urological Association,
J Y Zhang, and Y X Liu, and H Wang, and L Mi, and G H Song, and H F Jiang, and Y Yan, and B Shao, and W Y Kong, and R Y Zhang, and R Ran, and X R Liu, and J Wang, and Y T Lin, and H P Li
[Clinical study of recombinant human granulocyte colony stimulating factor (rhG-CSF) on leukopenia induced by chemotherapy in cancer patients].
May 1994, Zhonghua zhong liu za zhi [Chinese journal of oncology],
J Y Zhang, and Y X Liu, and H Wang, and L Mi, and G H Song, and H F Jiang, and Y Yan, and B Shao, and W Y Kong, and R Y Zhang, and R Ran, and X R Liu, and J Wang, and Y T Lin, and H P Li
Efficacy of recombinant granulocyte colony-stimulating factor (rhG-CSF) in experimental colitis.
December 1996, Clinical and experimental immunology,
J Y Zhang, and Y X Liu, and H Wang, and L Mi, and G H Song, and H F Jiang, and Y Yan, and B Shao, and W Y Kong, and R Y Zhang, and R Ran, and X R Liu, and J Wang, and Y T Lin, and H P Li
Treatment of methimazole-induced agranulocytosis using recombinant human granulocyte colony-stimulating factor (rhG-CSF).
November 1993, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!